Teva sues Mylan over attempt to make multiple sclerosis generic drug

JERUSALEM Teva Pharmaceutical Industries filed a lawsuit against U.S. generic drug maker Mylan for the latter’s attempt to market a generic version of a multiple sclerosis drug.

The Israeli drug maker filed suit against Mylan and Natco Pharma in the U.S. District Court for the Southern District of New York over Copaxone (glatiramer acetate), alleging that a regulatory approval application that Mylan filed with the Food and Drug Administration to market a generic version of the drug violated Teva’s patent.

Teva’s patent on Copaxone expires in May 2014. Teva said the filing was not unexpected, as Mylan had announced its intention to file the application more than a year ago.